![HeartSciences MyoVista wavECG Скачать руководство пользователя страница 28](http://html.mh-extra.com/html/heartsciences/myovista-wavecg/myovista-wavecg_user-manual_2114879028.webp)
19
USER MANUAL DO-LBL-06035(L)
| MyoVista® Wavelet ECG (
wav
ECG™) 12-Lead Cardiac Testing Device
General Overview
The MyoVista Summary Statement and Indicators provide an overall summary of all the
wav
ECG
Analysis . The statement categorizes the overall
wav
ECG Analysis results as either “Normal”,
“Borderline”, or “Abnormal” and is displayed in text as well as in a color-coded icon (see Figures 3-2,
3-3, 3-4) .
The summary represents the overall
wav
ECG Analysis results as performed by the software
algorithms . MyoVista version 2 .0 software contains algorithms which perform analysis relating to the
following:
• Repolarization Measures Algorithm (relaxation abnormalities associated with LV diastolic dysfunction)
Note: Future software releases may be expanded with additional algorithms for enhanced
detection of heart disease.
For patients which are not identified by the MyoVista Device as having a significantly elevated risk
of relaxation abnormalities associated with LV diastolic dysfunction, a classification of “Normal” is
displayed (see Figure 3-2) . This occurs when no abnormalities associated with MyoVista Measures,
Analysis and Algorithms are identified .
Note: This is not a “rule-out” measure, but rather a measure representing a lower risk of
relaxation abnormalities associated with LV diastolic dysfunction when compared to clinical
study patients whose categorizations are “Borderline” or “Abnormal” (as well as comparing
against the overall clinical study population).
Figure 3-2
For patients which are identified by the MyoVista Device as having an elevated risk of relaxation
abnormalities associated with LV diastolic dysfunction (or where a risk assessment is inconclusive),
a categorization of “Borderline” is displayed (see Figure 3-3) . In this case, additional statements
explaining the summary categorization will be provided, which include a Repolarization Measures
Statement and Ischemic or Structural risk assessment statement and may also include Ventricular
Indices Statement(s), if applicable . The relative-risk measure for “Borderline” patients when
compared to patients with a “Normal”
wav
ECG is provided in Table 3-1 (see page 21) .
Figure 3-3